Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

nt with Janssen, total amounts in excess of the annual cap ("Excess Amounts") plus interest may not exceed $225 million.

The Company has recognized the Excess Amounts as a reduction to operating expenses in the current year as the Company's repayment of the Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product under the collaboration. Further, the Excess Amounts shall be reimbursable only from the Company's share of future full calendar quarter pre-tax profits (if any) after the third profitable calendar quarter for the product under the collaboration.

For the calendar year ended December 31, 2012, the Company's total share of collaboration expenses under the Agreement was $68.1 million. As of December 31, 2012, total Excess Amounts totaled $18.1 million, of which during the quarter ended December 31, 2012, $17.3 million was recorded as a reduction to research and development expense and $0.8 million was recorded as a reduction to general and administrative expense.

GAAP operating expenses were $40.6 million for the six months ended December 31, 2012, compared to $30.6 million for the six months ended December 31, 2011. Included in operating expenses for the six months ended December 31, 2012 is the $18.1 million reduction to operating expenses for Excess Amounts.

GAAP operating expenses were $16.7 million for the quarter ended December 31, 2012, compared to $16.0 million for the quarter ended December 31, 2011 and $23.9 million for the quarter ended September 30, 2012. Included in operating expenses for the quarter ended December 31, 2012 is the $18.1 million reduction to operating expenses for the Excess Amounts.

At December 31, 2012, the Company had cash, cash equivalents and marketable securities of $317.1 million, compared with $203.6 million at June 30, 2012. In addition, as of December 31, 2012, the Company had $26.6 million receivable from Jansse
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
7. Pharmasset Reports Fiscal Year End 2011 Financial Results
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 EPFL ... announce the appointment of John P. Donoghue . ...   in  Geneva . The new ... Biotech in Geneva , has named ... neuroscientists. John P. Donoghue , founder of Brown ...
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... Poway, CA (PRWEB) July 10, 2014 Robert ... Regenerative Veterinary Medicine company, is proud to announce the relaunch ... Pets, launching with a new series called “ What are ... to give an honest and straightforward foundation in the basics ... an educated decision on the right type of treatment when ...
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
Breaking Biology Technology:John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... Wis. - After months of debate and restructuring Gov. ... - at the expense of the Biomedical Technology Alliance ... exercising a partial veto on a proposed grant of $2.5 ... investors located in southeastern Wisconsin. The partial veto will cut ...
... BIO 2005 meeting in Philadelphia last month, the globalization of ... flight. The company that perhaps best chronicles and tracks this ... biotechnology. , ,This report is usually released and previewed at ... appropriate title Beyond Borders: Global Biotechnology Report 2005, is a ...
... two-year state budget signed into law Monday by Gov. ... Wisconsin technology firms by changing how corporate income from ... Technology Council. , ,With bipartisan support from the ... factor" sales apportionment for corporate income to technology and ...
Cached Biology Technology:Doyle partially vetoes SE Wisconsin technology grant 2Doyle partially vetoes SE Wisconsin technology grant 3Globalization of biotech industry is a decidedly worldwide phenomenon 2Globalization of biotech industry is a decidedly worldwide phenomenon 3`Single-sales factor' extends tax treatment to tech, service firms 2`Single-sales factor' extends tax treatment to tech, service firms 3
(Date:7/11/2014)... Researchers from Ume University, Sweden, have explored two ... the reaction sequence leading to the formation of ... been published in the scientific journal Nature ... improving present day synthetic catalysts for water oxidation, ... devices for the direct storage of solar energy ...
(Date:7/11/2014)... the normal circumstances, astrocytes participate in normal ... and exhibit therapeutic and repairing effects on ... have found that nerve cells differentiated from ... reduced viability, which produces influences on subsequent ... General Hospital, Hebei United University, China demonstrated ...
(Date:7/10/2014)... and other major cities in New Mexico, nearly every ... wastewater rather than precious potable water supplies. Across the ... all golf courses receive treated effluent. Reusing the effluent ... golf courses and homeowners alike fertilize their lawns during ... nitrate. A New Mexico State University turfgrass expert has ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2'Tailored' water -- the latest in lawn care 2
... to find the necessities of life. It,s a complex task, ... environment to navigate the safest and fastest routes to food ... certain important events, such as finding a meal, will occur. ... fundamental behaviors, navigation and the anticipation of a reward, had ...
... /PRNewswire-iReach/ -- IdentiSys Inc., North America,s ... emergency response, and access control security systems, today announced ... in Customer and Patient Experience Management systems. IdentiSys will ... to the marketplace and will be the only North ...
... re-growing tropical forests has concluded that plant biodiversity takes ... such as clearance for farming. The findings, ... Royal Society B , have important implications for conservation ... and Central America. The new study is the first ...
Cached Biology News:Anticipation and navigation: Do your legs know what your tongue is doing? 2Anticipation and navigation: Do your legs know what your tongue is doing? 3Anticipation and navigation: Do your legs know what your tongue is doing? 4IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 2IdentiSys brings Qmatic Q-Guide Queuing Systems to the North American market 3Carbon storage recovers faster than plant biodiversity in re-growing tropical forests 2
... DNA Kit enables efficient extraction of DNA fragments from ... agarose gels. The procedure uses GelMelt solution to dissolve ... to a silica membrane in a spin column format. ... in low-salt buffer. Each spin column can bind up ...
... efficient extraction of DNA from agarose gels The ... fragments of 150 bp to > 12,000 bp in ... to dissolve the gel slice, followed by adsorption of ... column format. After a wash step, the purified DNA ...
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human HLA-DR TAC is designed to deplete human HLA-DR from samples to isolate resting CD4+ or CD8+ T cells....
BlotGel application pool -see Blotters (Semi-Dry) for more info...
Biology Products: